Aevisbio, Korea Research Institute of Chemical Technology patent new cereblon-targeting compounds

Oct. 25, 2024

Aevisbio Inc. and the Korea Research Institute of Chemical Technology have jointly developed new compounds targeting protein cereblon (CRBN) reported to be useful for the treatment of cancer.

BioWorld Science Cancer Patents

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 7, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 7, 2025

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...

Hummingbird migrates ADCs, tech to newco Callio’s $187M debut

BioWorld

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...